Serious early childhood wheezing after respiratory syncytial virus lower respiratory tract illness in preterm infants.
Respiratory syncytial virus (RSV) lower respiratory tract infection (LRI) in early life has been associated with sustained airway hyperreactivity during childhood; however, corresponding data in premature infants are sparse. The objective of this study was to determine whether RSV-LRI during early infancy of preterm infants was associated with an increased risk for serious early childhood wheezing (SECW) by age 3 years. A retrospective cohort study was conducted using data from a large (∼14 million members) US health plan database. The study population included infants ≤ 6 months of age born at ≤ 36 weeks' gestational age or weighing <2500 g, or both. Preterm infants with any medically attended RSV-LRI from May 2001 through April 2004 with 3 years of continuous eligibility were selected and propensity matched with ≤ 3 control infants. SECW was defined as >3 office, outpatient, or emergency department (ED) visits with asthma or wheezing; ≥ 1 office, outpatient, or ED visit with asthma or wheezing plus treatment with systemic corticosteroids within 7 days; ≥ 1 inpatient stay with asthma or wheezing; or ≥ 150 days' supply of asthma-control medications. The presence of SECW between ages 2 and 3 years was compared between infants with and without RSV-LRI using univariate and multivariate methods. Health care costs for patients with SECW were explored. A total of 378 infants with RSV were matched to 606 controls. The prevalence of SECW between ages 2 and 3 years was 16.7% in the RSV-LRI group versus 8.6% in the control group (P < 0.001). Logistic regression showed that preterm infants with RSV in early life were 2.52-fold (95% CI,1.65-3.85) more likely to present with SECW between ages 2 and 3 years (P < 0.001). Patients with SECW had a mean SECW-related cost of US $1378 (95% CI, $939-$1816) and total health care cost of $7138 (95% CI, $5087-$9189) compared with $37 (95% CI, $24-$51) and $2521 (95% CI, $1789-$3253), respectively, for patients without SECW. After adjusting for possible confounders, patients with SECW had a significantly higher total health care cost than did patients without evidence of SECW (P < 0.001). The development of RSV-LRI in infancy in preterm infants was associated with an increased prevalence of SECW between ages 2 and 3 years. Patients with SECW had higher total health care costs than those who did not have SECW.